Future for who. Not me dude. I am interviewing weekly for the first ticket off of this shit show of a 3 ring circus.
MedImmune has no new drugs coming on the market for at least the next 3 years. Pascal’s one-dimensional strategy is to squeeze as much as possible from existing oncology drugs and to start selling off low performing Resp and CVMet assets one by one to make quarterly earnings look good.
